Toxicological Profile for Chlorophenols

June 2022
DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and Agency for Toxic Substances and Disease Registry

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2022</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>July 2021</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>July 1999</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Malcolm Williams, D.V.M., Ph.D. (Lead)
Custodio Muianga, M.P.H., Ph.D., CHMM
ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Heather Carlson-Lynch, M.S., D.A.B.T.
Claire Heit, Ph.D.
Mario Citra, Ph.D.
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Water.

PEER REVIEWERS

1. Matt Simcik, Ph.D.; Professor, Division of Environmental Health Sciences; School of Public Health; University of Minnesota; Minneapolis, Minnesota
2. Ghulam Ahmad Shakeel Ansari, Ph.D.; Professor, Department of Pathology; The University of Texas Medical Branch; Galveston, Texas
3. Russell C. Cattley; Tyler & Frances Young Professor, V.M.D., Ph.D., DACVP; Head, Department of Pathobiology; College of Veterinary Medicine; Auburn University, Alabama

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DISCLAIMER</td>
<td>ii</td>
</tr>
<tr>
<td>FOREWORD</td>
<td>iii</td>
</tr>
<tr>
<td>VERSION HISTORY</td>
<td>v</td>
</tr>
<tr>
<td>CONTRIBUTORS &amp; REVIEWERS</td>
<td>vi</td>
</tr>
<tr>
<td>CONTENTS</td>
<td>vii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>ix</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>xi</td>
</tr>
</tbody>
</table>

### CHAPTER 1. RELEVANCE TO PUBLIC HEALTH

1.1 OVERVIEW AND U.S. EXPOSURES ...................................................... 1
1.2 SUMMARY OF HEALTH EFFECTS .......................................................... 2
1.3 MINIMAL RISK LEVELS (MRLs) ........................................................... 8

### CHAPTER 2. HEALTH EFFECTS

2.1 INTRODUCTION .................................................................................... 19
2.2 DEATH .................................................................................................. 75
2.3 BODY WEIGHT ..................................................................................... 80
2.4 RESPIRATORY ...................................................................................... 82
2.5 CARDIOVASCULAR ................................................................................. 85
2.6 GASTROINTESTINAL ............................................................................. 87
2.7 HEMATOLOGICAL .................................................................................. 88
2.8 MUSCULOSKELETAL ............................................................................. 90
2.9 HEPATIC ............................................................................................... 91
2.10 RENAL ................................................................................................. 97
2.11 DERMAL ............................................................................................. 99
2.12 OCULAR ............................................................................................. 100
2.13 ENDOCRINE ....................................................................................... 101
2.14 IMMUNOLOGICAL ............................................................................... 103
2.15 NEUROLOGICAL ................................................................................. 107
2.16 REPRODUCTIVE .................................................................................. 111
2.17 DEVELOPMENTAL ............................................................................... 118
2.18 OTHER NONCANCER .......................................................................... 123
2.19 CANCER .............................................................................................. 127
2.20 GENOTOXICITY .................................................................................. 133

### CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS

3.1 TOXICOKINETICS ................................................................................ 145
3.1.1 Absorption ..................................................................................... 145
3.1.2 Distribution ................................................................................... 147
3.1.3 Metabolism .................................................................................... 148
3.1.4 Excretion ....................................................................................... 151
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models ................................................................................................................. 153
3.1.6 Animal-to-Human Extrapolations .................................................. 153
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE .......................................................... 154
3.3 BIOMARKERS OF EXPOSURE AND EFFECT ........................................ 156
3.3.1 Biomarkers of Exposure .................................................................. 157
3.3.2 Biomarkers of Effect ...................................................................... 157
3.4 INTERACTIONS WITH OTHER CHEMICALS ........................................ 157
LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to 2-Chlorophenol........................................ 3
1-2. Health Effects Found in Animals Following Oral Exposure to 4-Chlorophenol........................................ 4
1-3. Health Effects Found in Animals Following Oral Exposure to 2,4-Dichlorophenol................................. 5
1-4. Health Effects Found in Animals Following Oral Exposure to 2,4,5-Trichlorophenol............................. 6
1-5. Health Effects Found in Animals Following Oral Exposure to 2,4,6-Trichlorophenol............................. 6
1-6. Health Effects Found in Animals Following Oral Exposure to 2,3,4,6-Tetrachlorophenol..................... 7
1-7. Health Effects Found in Animals Following Oral Exposure to Other Chlorophenols............................ 7
1-8. Summary of Sensitive Targets of 2-Chlorophenol – Oral ................................................................. 11
1-9. Summary of Sensitive Targets of 4-Chlorophenol – Oral ................................................................. 12
1-10. Summary of Sensitive Targets of 2,4-Dichlorophenol – Oral .......................................................... 13
1-11. Summary of Sensitive Targets of 2,4,5-Trichlorophenol – Oral ...................................................... 14
1-12. Summary of Sensitive Targets of 2,4,6-Trichlorophenol – Oral ...................................................... 15
1-13. Summary of Sensitive Targets of 2,3,4,6-Tetrachlorophenol – Oral ................................................ 16
2-1. Overview of the Number of Studies Examining 2-Chlorophenol Health Effects................................. 23
2-2. Overview of the Number of Studies Examining 4-Chlorophenol Health Effects................................. 24
2-3. Overview of the Number of Studies Examining 2,4-Dichlorophenol Health Effects ............................ 25
2-4. Overview of the Number of Studies Examining 2,4,5-Trichlorophenol Health Effects ......................... 26
2-5. Overview of the Number of Studies Examining 2,4,6-Trichlorophenol Health Effects ......................... 27
2-6. Overview of the Number of Studies Examining 2,3,4,6-Tetrachlorophenol Health Effects ................... 28
2-7. Overview of the Number of Studies Examining Other Chlorophenol Health Effects......................... 29
2-8. Levels of Significant Exposure to Chlorophenols – Inhalation .......................................................... 31
2-9. Levels of Significant Exposure to 2-Chlorophenol – Oral ................................................................. 36
2-10. Levels of Significant Exposure to 4-Chlorophenol – Oral ............................................................... 42
2-11. Levels of Significant Exposure to 2,4-Dichlorophenol – Oral .......................................................... 50
2-12. Levels of Significant Exposure to 2,4,5-Trichlorophenol – Oral ...................................................... 56
2-13. Levels of Significant Exposure to 2,4,6-Trichlorophenol – Oral ...................................................... 61
2-14. Levels of Significant Exposure to 2,3,4,6-Tetrachlorophenol – Oral...................................................... 67
2-15. Levels of Significant Exposure to Other Chlorophenols – Oral .......................................................... 72
5-1. Number of NPL Sites with Chlorophenols Contamination .................................................................. 167
6-1. Summary of Existing Health Effects Studies on 2-Chlorophenol By Route and Endpoint................. 220
6-2. Summary of Existing Health Effects Studies on 4-Chlorophenol By Route and Endpoint............... 221
6-3. Summary of Existing Health Effects Studies on 2,4-Dichlorophenol By Route and Endpoint........... 222
6-4. Summary of Existing Health Effects Studies on 2,4,5-Trichlorophenol By Route and Endpoint...... 223
6-5. Summary of Existing Health Effects Studies on 2,4,6-Trichlorophenol By Route and Endpoint...... 224
6-6. Summary of Existing Health Effects Studies on 2,3,4,6-Trichlorophenol By Route and Endpoint..... 225
6-7. Summary of Existing Health Effects Studies on Other Chlorophenols By Route and Endpoint...... 226
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Chlorophenols ................................................................. 17
2-1. Levels of Significant Exposure to Chlorophenols – Inhalation .................................................. 30
2-2. Levels of Significant Exposure to 2-Chlorophenol – Oral ............................................................. 32
2-3. Levels of Significant Exposure to 4-Chlorophenol – Oral ............................................................. 39
2-4. Levels of Significant Exposure to 2,4-Dichlorophenol – Oral ....................................................... 44
2-5. Levels of Significant Exposure to 2,4,5-Trichlorophenol – Oral .................................................... 54
2-6. Levels of Significant Exposure to 2,4,6-Trichlorophenol – Oral .................................................... 57
2-7. Levels of Significant Exposure to 2,3,4,6-Tetrachlorophenol – Oral .............................................. 64
2-8. Levels of Significant Exposure to Other Chlorophenols – Oral ...................................................... 70
2-9. Levels of Significant Exposure to Chlorophenols – Dermal ............................................................ 73
2-10. Comparisons Among Oral LD50 Values for Chlorophenols .......................................................... 75
2-11. Relationship Between Degree of Chlorination and Symptoms of Uncoupling in Rats Exposed by Intraperitoneal Injection .............................................................. 124
2-12. Genotoxicity of 2-Chlorophenol In Vitro .................................................................................... 134
2-13. Genotoxicity of 4-Chlorophenol In Vitro ..................................................................................... 135
2-14. Genotoxicity of 2,4-Dichlorophenol In Vitro ................................................................................ 137
2-15. Genotoxicity of 2,5- Dichlorophenol In Vitro ............................................................................. 139
2-16. Genotoxicity of 2,4,5-Trichlorophenol In Vitro .......................................................................... 139
2-17. Genotoxicity of 2,4,6-Trichlorophenol In Vitro .......................................................................... 141
2-18. Genotoxicity of Other Chlorophenols In Vitro .......................................................................... 143
4-1. Chemical Identity of Chlorophenol Compounds ........................................................................ 160
4-2. Physical and Chemical Properties of Chlorophenol Compounds .................................................. 162
5-1. Facilities that Produce, Process, or Use Chlorophenols ................................................................. 170
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Chlorophenols .......... 172
5-3. Degradation of Chlorophenols by Bacteria Adapted to Pentachlorophenol Under Different Oxygen Conditions ............................................................................................................ 182
5-4. Lowest Limit of Detection Based on Standards ............................................................................ 185
5-5. Summary of Environmental Levels of Chlorophenols ................................................................. 185

5-6. Chlorophenols Levels in Water, Soil, and Air of National Priorities List (NPL) Sites ........ 186

5-7. Levels of Chlorophenols in Atmosphere of Samples Collected in Winter 2004 in Strasbourg, France ................................................................................................................................. 187

5-8. Geometric Mean and Selected Percentiles of Urinary 2,4-Dichlorophenol Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016 ................................................................. 194

5-9. Geometric Mean and Selected Percentiles of Urinary 2,4-Dichlorophenol Concentrations (Creatinine Corrected) (in µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016 ................................................................. 197

5-10. Geometric Mean and Selected Percentiles of Urinary 2,5-Dichlorophenol Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016 ................................................................. 200

5-11. Geometric Mean and Selected Percentiles of Urinary 2,5-Dichlorophenol Concentrations (Creatinine Corrected) (in µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2003–2016 ................................................................. 203

5-12. Geometric Mean and Selected Percentiles of Urinary 2,4,5-Trichlorophenol Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010 ................................................................................................. 206

5-13. Geometric Mean and Selected Percentiles of Urinary 2,4,5-Trichlorophenol Concentrations (Creatinine Corrected) (in µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010 ................................................................................................. 208

5-14. Geometric Mean and Selected Percentiles of Urinary 2,4,6-Trichlorophenol Concentrations (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010 ................................................................................................. 211

5-15. Geometric Mean and Selected Percentiles of Urinary 2,4,6-Trichlorophenol Concentrations (Creatinine Corrected) (in µg/g of Creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2010 ................................................................................................. 213

5-16. Urinary Concentrations (µg/L) from 485 Subjects in the GerES V Study ........................................... 216

6-1. Ongoing Study of 2,4- and 2,5-Dichlorophenol ............................................................................. 234

7-1. Regulations and Guidelines Applicable to Chlorophenols .................................................................. 235